非免疫原性葡萄球菌激酶用于急性缺血性卒中溶栓的FORPI注册研究
结果显示症状性颅内出血率2%,90天全因死亡率9%,90天功能独立(mRS 0-2)率61%,与FRIDA随机试验结果相当。提示该药在症状发作4.5小时内溶栓安全有效。
要点
- 非免疫原性葡萄球菌激酶溶栓后症状性颅内出血率2%,90天死亡率9%。
- 90天功能独立(mRS 0-2)率为61%。
- 安全性和有效性结局与FRIDA随机试验结果相当。
核心结论
- 非免疫原性葡萄球菌激酶在AIS症状发作4.5小时内静脉溶栓在常规临床实践中安全有效。
主要发现
- 中位年龄68岁(60-75),男性56%,中位基线NIHSS评分11分(8-16),中位发病至治疗时间2.4小时(1.8-3.1)。
- 上述安全性和有效性结局与FRIDA随机临床试验结果相当。
关键数值与推荐
- 非免疫原性葡萄球菌激酶获批用于AIS症状发作4.5小时内溶栓治疗。
- 症状性颅内出血分别按ECASS III和SITS-MOST标准评估,观察窗为36小时。
- 有效性结局采用90天mRS 0-2定义功能独立。
临床怎么用
- 对于适合溶栓的AIS患者,可考虑在症状发作4.5小时内使用非免疫原性葡萄球菌激酶进行静脉溶栓。
局限性
- 本研究为观察性注册研究,非随机对照设计,可能存在选择偏倚和未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The non-immunogenic staphylokinase is a recombinant staphylokinase with low immunogenicity, high thrombolytic activity, and fibrin selectivity approved in Russia for the acute ischemic stroke (AIS) thrombolytic therapy within 4.5 hours after symptom onset. We evaluated safety and efficacy outcomes of the non-immunogenic staphylokinase usage in patients with AIS in the Fortelyzin Population Investigation registry. METHODS: Between March 2021 and October 2024, patients with AIS treated with the non-immunogenic staphylokinase were enrolled in the prospective, open-label, internet-based, monitored, observational Fortelyzin Population Investigation registry. Demographics, risk factors, baseline stroke severity (defined by National Institutes of Health Stroke Scale), and onset to treatment time were recorded. Safety outcomes included symptomatic intracerebral hemorrhage (according to the ECASS III [European Cooperative Acute Stroke Study III] and SITS-MOST [Safe Implementation of Thrombolysis in Stroke-Monitoring Study] criteria) within 36 hours and all-cause mortality on day 90. Efficacy outcome was evaluated by functional independence using of modified Rankin Scale score of 0 to 2 on day 90. RESULTS: A total of 17 636 patients with AIS were treated with the non-immunogenic staphylokinase in 329 centers participated in the Fortelyzin Population Investigation registry during the study period (median age 68 [60-75]; 56% male; median baseline National Institutes of Health Stroke Scale score, 11 [8-16] points; median onset to treatment time, 2.4 hours [1.8-3.1]). The rate of symptomatic intracerebral hemorrhage according to the ECASS III criteria was 2% (356/17 636; 1.8-2.2), to the SITS-MOST criteria, 2% (330/17 636; 1.8-2.1). All-cause mortality on day 90 was 9% (1588/17 636; 8.6-9.4). The number of patients with a modified Rankin Scale score of 0 to 2 on day 90 was 61% (10 799/17 636; 60.5-61.9). These safety and efficacy outcomes were comparable with FRIDA (Fortelyzin Randomized Investigation Compared With Alteplase) randomized clinical trial results. CONCLUSIONS: The presented data suggest that intravenous thrombolysis with the non-immunogenic staphylokinase is safe and effective in routine clinical practice when used within 4.5 hours of AIS symptoms onset. These findings should encourage the wider usage of thrombolytic therapy with the non-immunogenic staphylokinase for suitable patients. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06707987.
引用
- Shamalov NA, Martynov MY, Yarovaya EB, et al. Thrombolysis With the Non-Immunogenic Staphylokinase for Acute Ischemic Stroke in the FORPI Registry: An Observational Study. Stroke. 2025. PMID: 41293810. doi:10.1161/STROKEAHA.125.051115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。